Home / Stocks / Ipca Laboratories Ltd
IPCALAB

Ipca Laboratories Ltd Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹1,860.0

Change

+5.9 (0.32%)

Open

₹1,857.6

Prev. Close

₹1,854.1

Day High

₹1,890.5

Day Low

₹1,845.1

Volume Analysis

Traded

257,674

Delivered

176,977

Delivery %

68.68%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (1)

  • •Strong operating margin (23.0%)

Weaknesses (1)

  • •Promoter holding is falling

Opportunities (3)

  • •Strong 3-year EPS growth (34.3%)
  • •Strong 3-year revenue growth (15.7%)
  • •FII holding has been rising

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹1,930.7 ₹1,910.6 ₹1,885.3 ₹1,865.2 ₹1,839.9 ₹1,819.8 ₹1,794.5
Fibonacci ₹1,910.6 ₹1,893.26 ₹1,882.54 ₹1,865.2 ₹1,847.86 ₹1,837.14 ₹1,819.8
Camarilla ₹1,872.49 ₹1,868.32 ₹1,864.16 ₹1,865.2 ₹1,855.84 ₹1,851.68 ₹1,847.52

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+33.03%

1 Week

-2.09%

1 Month

-3.07%

3 Months

-2.68%

6 Months

+16.1%

1 Year

+29.33%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹588.32

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

15.61%

Net margin 14.16% × asset turnover 0.73x × equity multiplier 1.51x

Company Overview

Sector

Healthcare

Market Cap

₹46,508 Cr

P/E (TTM)

32.3

ROE

15.7%

Book Value

₹342.0

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.

TopFund Analysis

Ipca Laboratories Ltd holds up reasonably well on TopFund's composite fundamentals check within the Healthcare sector, at 69/100. The strongest factor is Financial Strength (100/100), while Valuation (34/100) is the weakest area to weigh before deciding. Notably: Strong operating margin (23.0%); promoter holding is falling. Strong 3-year EPS growth (34.3%).

TopFund Score — Fundamentals Quality

69/100 — Good

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

59

Valuation

34

Cash Flow

41

Corporate Governance

43

Momentum

70

Institutional Ownership

84

Business Quality

78

Risk & Volatility

83

Liquidity

98

From Screener.in

  • +Company has reduced debt.
  • +Company is almost debt free.
  • −Stock is trading at 5.36 times its book value
  • −Company has a low return on equity of 12.9% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Ipca Labs held Q2 FY27 earnings call; consolidated revenue rose 14% to INR2,910 crore, EBITDA margin 22.97%.

Audio link shared for Q2FY27 earnings and business update conference call held on November 5, 2026.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 2,034 2,053 2,033 2,093 2,355 2,245 2,247 2,309 2,556 2,392 2,388 2,788 2,910
Expenses + 1,673 1,722 1,711 1,700 1,913 1,782 1,818 1,892 2,012 1,859 1,905 2,119 2,236
Operating Profit 361 331 322 393 441 463 429 416 545 533 484 670 673
OPM % 18.0% 16.0% 16.0% 19.0% 19.0% 21.0% 19.0% 18.0% 21.0% 22.0% 20.0% 24.0% 23.0%
Other Income + -1 91 -118 21 26 20 -179 33 -30 38 48 25 1
Interest 44 33 29 24 23 17 22 19 20 18 20 12 13
Depreciation 90 100 98 99 100 98 100 100 103 108 107 111 115
Profit before tax 225 289 77 290 345 368 128 331 392 446 404 572 547
Tax % 39.0% 23.0% 96.0% 31.0% 29.0% 25.0% 49.0% 29.0% 28.0% 18.0% 24.0% 26.0% 28.0%
Net Profit + 136 221 1 199 246 276 64 233 281 364 307 424 389
EPS in Rs 6 7 2 8 9 10 3 9 11 13 12 16 15
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 27 33 34 32 16 9 11 10 9 7 6 21 14

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 3,144 2,867 3,156 3,258 3,746 4,619 5,395 5,797 6,204 7,662 8,897 9,599 10,479
Expenses + 2,604 2,573 2,705 2,803 3,051 3,715 3,843 4,472 5,272 6,338 7,166 7,609 8,119
Operating Profit 541 294 451 455 695 904 1,552 1,325 932 1,324 1,731 1,990 2,360
OPM % 17.0% 10.0% 14.0% 14.0% 19.0% 20.0% 29.0% 23.0% 15.0% 17.0% 19.0% 21.0% 23.0%
Other Income + 32 21 11 41 56 65 59 54 123 17 -114 80 112
Interest 32 35 27 28 22 20 12 11 48 141 88 79 62
Depreciation 180 163 173 178 182 210 209 232 262 357 398 418 440
Profit before tax 361 117 262 291 546 739 1,389 1,136 745 843 1,131 1,573 1,970
Tax % 28.0% 18.0% 26.0% 18.0% 19.0% 18.0% 17.0% 20.0% 34.0% 37.0% 30.0% 24.0% —
Net Profit + 254 93 195 239 442 604 1,141 890 479 523 785 1,184 1,484
EPS in Rs 10 4 8 9 18 24 45 35 19 22 29 45 55
Dividend Payout % 5.0% 0.0% 6.0% 5.0% 9.0% 10.0% 9.0% 11.0% 22.0% 19.0% 14.0% 0.0% —
Sales growth -4 -9 10 3 15 23 17 7 7 24 16 8 12

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 2,183 2,234 2,430 2,663 3,097 3,602 4,676 5,467 5,817 6,307 6,923 8,038 8,653
Borrowings + 935 867 716 628 465 501 265 807 1,481 1,438 1,363 809 753
Other Liabilities + 669 765 788 799 961 1,130 1,099 1,338 1,300 3,326 3,432 3,477 3,702
Total Liabilities 3,812 3,892 3,960 4,116 4,549 5,258 6,066 7,637 8,623 11,097 11,744 12,350 13,133
Fixed Assets + 1,800 2,014 1,983 1,953 1,940 2,059 2,072 2,418 2,751 4,554 4,267 4,627 4,740
CWIP 267 129 95 73 66 133 235 306 140 343 622 773 832
Investments 16 26 136 87 120 310 505 989 626 862 980 844 1,055
Other Assets + 1,729 1,723 1,746 2,003 2,422 2,756 3,254 3,924 5,105 5,339 5,875 6,106 6,507
Total Assets 3,812 3,892 3,960 4,116 4,549 5,258 6,066 7,637 8,623 11,097 11,744 12,350 13,133
Equity Capital 25 25 25 25 25 25 25 25 25 25 25 25 25

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 468 709 282 341 501 570 1,090 856 806 945 1,321 1,142
Cash from Investing Activity + -689 -218 -149 -135 -165 -509 -521 -851 -725 -1,215 -870 -247
Cash from Financing Activity + 251 -462 -159 -130 -183 -137 -306 427 507 -553 -283 -754
Net Cash Flow 29 29 -26 75 153 -76 264 432 588 -823 169 142
Free Cash Flow -207 463 147 206 322 277 731 380 347 543 551 486
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 100 251 74 88 88 80 86 80 110 94 97 78

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 46.29% → 44.72%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 8.93% 8.82% 9.07% 8.64% 8.53% 8.45% 8.41% 8.09% 7.33% 7.21% 7.19% 7.15%
Promoters 46.29% 46.3% 46.3% 46.3% 44.72% 44.72% 44.72% 44.72% 44.72% 44.72% 44.72% 44.72%
Government 0.32% 0.32% 0.32% 0.32% 0.32% 0.32% 0.32% 0.32% 0.32% 0.32% 0.32% 0.0%
FII 10.27% 10.51% 10.85% 10.83% 11.06% 10.75% 10.67% 10.42% 10.62% 10.63% 10.72% 11.53%
DII 34.19% 34.05% 33.46% 33.9% 35.36% 35.73% 35.88% 36.45% 36.99% 37.13% 37.04% 36.6%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Ipca Laboratories Ltd (this stock) 46,508 32.3 5.36 15.7%
Glaxosmithkline Pharma Lt 45,576 40.2 24.22 45.6%
Emcure Pharmaceuticals L 44,370 39.9 8.29 20.1%
Anthem Biosciences Ltd 51,355 81.4 15.65 22.3%
Ajanta Pharma Limited 41,393 32.8 8.51 27.1%
Sai Life Sciences Limited 41,003 107.0 15.19 15.4%
Gland Pharma Limited 53,710 42.9 5.01 10.7%

Which Mutual Funds Hold Ipca Laboratories Ltd?

Frequently Asked Questions about Ipca Laboratories Ltd

Community Sentiment

What are other investors saying about Ipca Laboratories Ltd?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.